Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Signet Laboratories Announces Availability of Monoclonal Cyclin E

  Leading medical diagnostics/research company announces the availability of
                   monoclonal antibody Cyclin E, clone HE12

    DEDHAM, Mass., Jan. 24 /PRNewswire/ -- Signet Laboratories, Inc., a
leading medical diagnostics/research company specializing in the development
of monoclonal antibodies and diagnostic assays for cancer, infectious disease,
and neurodegenerative disease, today announced the availability of monoclonal
Cyclin E antibody.
    Cyclin E, clone HE12, is a cell cycle protein that regulates G1-S phase
transition in mammalian cells and is required for DNA synthesis.  Aberrant
expression of Cyclin E has been demonstrated in a multitude of malignancies.
    Studies have implicated Cyclin E as a marker of unfavorable prognosis for
some cancers, including breast and lung cancer.  Signet's Cyclin E, clone
HE12, recognizes human Cyclin E.
    Signet's Cyclin E antibody offers investigators a valuable tool for cancer
research.  Cyclin E complements Signet's current cancer and cell cycle product
portfolio which includes markers such as Cyclin D1, Cyclin E, HE4 and Hepsin.

    About Signet Laboratories, Inc.
    Signet Laboratories, Inc. (Signet, Dedham, MA) is a leading medical
diagnostics/research company specializing in the development of monoclonal
antibodies and diagnostic assays for cancer, infectious disease, and
neurodegenerative disease. Signet was created in 1989 as a commercial spinout
of Johnson & Johnson's Cambridge Research Laboratories, Inc. (CRL, Cambridge,
MA).
    The Company was founded to continue the mission originally established at
CRL-the early detection and recurrence monitoring of patients with cancer and
infectious disease. Signet has developed patented technology for diagnosis and
recurrence monitoring and for risk assessment of asymptomatic patients in
these areas. For more than a decade, the Company has aggressively maintained
licensing and development programs, which are responsible for its broad patent
and intellectual estate.

    Contact Information
     Company Contact                Immunohistochemistry Contact
     Colleen Scott                  Angela Thomas
     Signet Laboratories, Inc.      Signet Laboratories, Inc.
     180 Rustcraft Road             180 Rustcraft Road
     Dedham, MA 02026               Dedham, MA 02026
     Phone: 781.915.1404            Phone: 781.915.1417
     Fax:  781.461.2456             Fax:  781.461.2456
     cscott@signetlabs.com          athomas@signetlabs.com


SOURCE Signet Laboratories, Inc.




Back to Topback to top

Related links:
  • http://www.signetlabs.com
    CONTACT:
    Company contact: Colleen Scott,
    +1-781-915-1404, cscott@signetlabs.com, or Immunohistochemistry
    contact: Angela Thomas, +1-781-915-1417, athomas@signetlabs.com,
    both of Signet Laboratories, Inc.